Sleep apnoea syndrome - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Sleep apnoea syndrome – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Sleep apnoea syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Sleep apnoea syndrome: Overview
Sleep apnea is a serious sleep disorder that occurs when a person's breathing is interrupted during sleep. People with untreated sleep apnea stop breathing repeatedly during their sleep. There are two types of sleep apnea: Obstructive sleep apnea (OSA): The more common of the two forms of apnea, it is caused by a blockage of the airway, usually when the soft tissue in the back of the throat collapses during sleep. Central sleep apnea: Unlike OSA, the airway is not blocked, but the brain fails to signal the muscles to breathe, due to instability in the respiratory control center. All three types of sleep apnea share certain common symptoms: Disrupted breathing in which a person’s respiration can become labored or even stop for up to a minute at a time, Excessive daytime sleepiness, Morning headaches, Irritability, and Limited attention span or difficulty thinking clearly. Treatment aims to normalize breathing during sleep and address any underlying health problems.
'Sleep apnoea syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sleep apnoea syndrome pipeline landscape is provided which includes the disease overview and Sleep apnoea syndrome treatment guidelines. The assessment part of the report embraces, in depth Sleep apnoea syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sleep apnoea syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Sleep apnoea syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sleep apnoea syndrome Emerging Drugs
Further product details are provided in the report
Sleep apnoea syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Sleep apnoea syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Sleep apnoea syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sleep apnoea syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sleep apnoea syndrome drugs.
Sleep apnoea syndrome Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Sleep apnoea syndrome – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Sleep apnoea syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Sleep apnoea syndrome: Overview
Sleep apnea is a serious sleep disorder that occurs when a person's breathing is interrupted during sleep. People with untreated sleep apnea stop breathing repeatedly during their sleep. There are two types of sleep apnea: Obstructive sleep apnea (OSA): The more common of the two forms of apnea, it is caused by a blockage of the airway, usually when the soft tissue in the back of the throat collapses during sleep. Central sleep apnea: Unlike OSA, the airway is not blocked, but the brain fails to signal the muscles to breathe, due to instability in the respiratory control center. All three types of sleep apnea share certain common symptoms: Disrupted breathing in which a person’s respiration can become labored or even stop for up to a minute at a time, Excessive daytime sleepiness, Morning headaches, Irritability, and Limited attention span or difficulty thinking clearly. Treatment aims to normalize breathing during sleep and address any underlying health problems.
'Sleep apnoea syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sleep apnoea syndrome pipeline landscape is provided which includes the disease overview and Sleep apnoea syndrome treatment guidelines. The assessment part of the report embraces, in depth Sleep apnoea syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sleep apnoea syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Sleep apnoea syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Sleep apnoea syndrome.
This segment of the Sleep apnoea syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sleep apnoea syndrome Emerging Drugs
- AD128: Apnimed
- BAY2586116: Bayer
Further product details are provided in the report
Sleep apnoea syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Sleep apnoea syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Sleep apnoea syndrome
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Sleep apnoea syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sleep apnoea syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sleep apnoea syndrome drugs.
Sleep apnoea syndrome Report Insights
- Sleep apnoea syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Sleep apnoea syndrome drugs?
- How many Sleep apnoea syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sleep apnoea syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sleep apnoea syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sleep apnoea syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Sleep apnoea syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Sleep apnoea syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Sleep apnoea syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Sleep apnoea syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase II/III)
Comparative Analysis
AD128: Apnimed
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
BAY2586116: Bayer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
Gefapixant: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Sleep apnoea syndrome Key Companies
Sleep apnoea syndrome Key Products
Sleep apnoea syndrome- Unmet Needs
Sleep apnoea syndrome- Market Drivers and Barriers
Sleep apnoea syndrome- Future Perspectives and Conclusion
Sleep apnoea syndrome Analyst Views
Sleep apnoea syndrome Key Companies
Appendix
Executive Summary
Sleep apnoea syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Sleep apnoea syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Sleep apnoea syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Sleep apnoea syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase II/III)
Comparative Analysis
AD128: Apnimed
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
BAY2586116: Bayer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
Gefapixant: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Sleep apnoea syndrome Key Companies
Sleep apnoea syndrome Key Products
Sleep apnoea syndrome- Unmet Needs
Sleep apnoea syndrome- Market Drivers and Barriers
Sleep apnoea syndrome- Future Perspectives and Conclusion
Sleep apnoea syndrome Analyst Views
Sleep apnoea syndrome Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Sleep apnoea syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Sleep apnoea syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Sleep apnoea syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Sleep apnoea syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
